Match Document Document Title
9040084 Pharmaceutical formulation containing gelling agent  
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically...
9034376 Pharmaceutical formulation containing gelling agent  
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically...
9034377 Opioid dosage forms having dose proportional steady state Cave and AUC and less than dose proportional single dose Cmax  
The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage...
9034893 Process for reducing contaminating michael acceptor levels in oxycodone and other compositions  
The present invention relates to processes for removal of Michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions...
9023860 Pro-drugs for controlled release of biologically active compounds  
Pro-drugs containing an electron withdrawing substituent, as defined in the specification, are useful in a method for providing a patient with post administration-activated, controlled release of...
9023394 Formulations and methods for the controlled release of active drug substances  
Controlled release formulations and methods for preparing controlled release formulations for delivery of active drug substances are described herein. The formulations described herein may be...
9012468 One pot process for producing 6-hydroxyl nal-opiate  
The present invention provides processes for preparing nal-opiates without the isolation of intermediates. In general, the process provides for alkylation and reduction in the same pot to give the...
9012469 Crystalline naloxol-peg conjugate  
Naloxol-polyethlyene glycol conjugates of the formula: are provided in oxalate or phosphate salt forms including crystalline forms. Methods of preparing the salt forms and pharmaceutical...
9005660 Immediate release composition resistant to abuse by intake of alcohol  
The present invention relates to immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol. In particular, this disclosure provides...
9005659 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Pharmaceutical formulation containing gelling agent
 
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically...
8999961 Pharmaceutical formulation containing gelling agent  
Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically...
8987328 Esters of capsaicinoids as dietary supplements  
Provided are nutraceutical or dietary supplemental compositions comprising esterified capsaicinoids. The esterified capsaicinoids may converted to the active parent capsaicinoid compound following...
8987291 Opioid-containing oral pharmaceutical compositions and methods  
The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an opioid (including salts...
8987290 Use of opioid formulations in needle-less drug delivery devices  
The present invention concerns a needle-less drug delivery device being suitable for delivering drugs through a skin surface into a human or animal body comprising a pharmaceutical composition...
8987289 Methods for treating pruritus  
The present invention relates to methods for treating pruritus with anti-pruritic compositions.
8980907 Dendrimer conjugates  
The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same,...
8980291 Controlled release hydrocodone formulations  
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt...
8980908 Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation  
Selective, non-peptide antagonists of the mu opioid receptor (MOR) and methods of their use are provided. The antagonists may be used, for example, to identify MOR agonists in competitive binding...
8980319 Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans  
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form...
8980305 Non-abusable pharmaceutical composition comprising opioids  
There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof,...
8980880 Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder  
A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound...
8975273 Controlled release hydrocodone formulations  
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt...
8975271 ***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Controlled release hydrocodone formulations
 
A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt...
8975257 Methods for making 3-O-protected morphinones and 3-O-protected morphinone dienol carboxylates  
Disclosed are methods for making aldehydes and ketones comprising allowing the corresponding primary or secondary alcohol to react in the presence of trichoroisocyanuric acid, a compound of...
8975270 Injectable flowable composition comprising buprenorphine  
The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to...
8974821 Oral drug delivery system  
Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.
8975272 Polymorphic forms of naltrexone  
This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of...
8969370 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists  
The invention provides 3-carboxypropyl-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt thereof,...
8969369 Abuse-resistant controlled-release opioid dosage form  
Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if...
8969368 Crystalline, anhydrous forms of oxymorphone hydrochloride  
Crystalline, anhydrous hydrochloride salts of 4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one (oxymorphone) are disclosed and three polymorphic forms of these salts are reported. The invention...
8969371 Compositions and methods for weight loss in at risk patient populations  
The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse...
8969367 Crystalline forms of a 3-carboxypropyl-aminotetralin compound  
The invention provides crystalline solid forms of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tet rahydronaphthalen-2-ylamino)-2-cyclohexylmethyl-butyric acid. The invention also...
8962646 Peripherally acting opioid compounds  
The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:
8962647 Conjugate of polyethylene gylcol and naloxone and pharmaceutical composition and use thereof  
Provided are a PEG-naloxone conjugate of general formula (II) and a pharmaceutical composition comprising the conjugate. In the conjugate, n is an integer in the range of 1-20. Also provided is a...
8956651 Oral formulations and lipophilic salts of methylnal trexone  
The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
8957085 Carboxamide bioisosteres of opiates  
A compound of formula I is disclosed. Compounds of formula I are useful as analgesics, anti-inflammatory agents, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.
8951556 Oral drug delivery system  
Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.
8952031 Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists  
The invention provides amino- and amido-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt...
8952032 Oligomer-opioid agonist conjugates  
The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of...
8951557 Sustained release solid formulations and methods of manufacturing the same  
Disclosed are a sustained release solid formulation comprising a drug, for example, oxycodone or its pharmaceutically acceptable salt, in a water-insoluble matrix, which comprises a wax type...
8946253 Systems and methods for treating an opioid-induced adverse pharmacodynamic response  
Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount...
8946254 Bivalent ligands for the treatment of neurological disorders  
Bivalent ligands that contain two pharmacophores linked through a spacer, one of which interacts with the μ-opioid receptor (MOR) and the other of which interacts with the co-receptor CC chemokine...
8945614 Oral drug delivery system  
Dosage forms and drug delivery devices suitable for administration of pharmaceutical compounds and compositions, including the oral drug administration of compounds.
8940753 Methods for treating pruritis  
The present invention relates to methods for treating pruritus with anti-pruritic compositions.
8940330 Abuse-resistant pharmaceutical composition for the treatment of opioid dependence  
There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a...
8940729 Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder  
A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound...
8936812 Tamper-resistant oral opioid agonist formulations  
Disclosed is a substantially non-releasable form of an opioid antagonist containing the opioid antagonist combined with one or more pharmaceutically acceptable hydrophobic material(s) such that...
8933092 Methods and compositions comprising sequential administration opioid receptor agonists  
Methods and compositions for the alleviation of pain in a patient. The methods and compositions sequentially administer a therapeutically effective amount of first compound having opioid receptor...
8927011 Method for producing pharmaceutical tablet  
A process for advantageously producing tablets having an improved release property and an excellent stability to change with time is provided. The process is for producing tablets containing a...
8920836 Particulates  
A neutral poly(ethyl acrylate, methyl methacrylate) copolymer is employed as a carrier in the manufacture of pharmaceutical formulations containing an active ingredient. The formulations are...